Top Markets
#1 TENDIES TENDIES +37.02%
#2 Cash Cat Cash Cat +24.00%
#3 Asteroid Shiba Asteroid Shiba +16.86%
#4 OSK OSK +15.36%
#5 龙虾 (Lobster) 龙虾 (Lobster) +11.30%
#6 Bluwhale Bluwhale +10.73%
#7 MarsCoin MarsCoin +8.62%
#8 ROLL ROLL +7.54%
#9 CARV CARV +7.24%
#10 Pyth Network Pyth Network +7.13%
Coin of the day
TENDIES TENDIES
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
NervGen Pharma Corp. NervGen Pharma Corp.

NervGen Pharma Corp.

NGEN
Kedudukan dalam Saham #16730
NervGen Pharma Corp., along with its affiliated entities, is a pharmaceutical... NervGen Pharma Corp., along with its affiliated entities, is a pharmaceutical company dedicated to discovering, advancing, and commercializing innovative drug therapies for neurological conditions involving nerve damage. Its flagship investigational therapy, NVG-291, is currently undergoing Phase 1 clinical trials, targeting significant neurological disorders such as spinal cord injuries (SCI), multiple sclerosis, and Alzheimer's disease. NervGen has also secured an exclusive licensing agreement with Case Western Reserve University. This partnership enables the company to research, advance, and commercialize a proprietary technology holding considerable therapeutic promise for SCI and a range of other nerve-related ailments. Established in 2017, NervGen Pharma Corp. maintains its headquarters in Vancouver, Canada.
Harga Saham
$3.78
Disegerakkan terakhir: 2026-03-17
Modal Pasaran
$276.54M
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
45.53%
Negara
CA
Perdagangan NervGen Pharma Corp. (NGEN)

Kategori

Healthcare
Hasil untuk NervGen Pharma Corp. (NGEN)
Hasil pada Sep 2026 TTM: 0
Menurut laporan kewangan terkini daripada NervGen Pharma Corp., hasil semasa syarikat (TTM) ialah 0. Pada tahun 2026, syarikat memperoleh hasil sebanyak 0 sama dengan hasil pada tahun 2026 iaitu 0. Hasil ialah jumlah pendapatan keseluruhan yang dijana oleh syarikat daripada jualan barangan atau perkhidmatan. Tidak seperti keuntungan, tiada perbelanjaan ditolak.
Sejarah hasil bagi NervGen Pharma Corp. dari 2026 hingga 2026
Hasil pada akhir setiap tahun
Tahun Hasil Ubah
Tidak cukup data untuk tarikh yang disediakan.
Hasil untuk syarikat atau pesaing serupa
Syarikat Hasil Perbezaan Hasil Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH